Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.

@article{Chataway2018EffectsOA,
  title={Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.},
  author={Jeremy Chataway and Keith R Martin and Kevin Barrell and Basil Sharrack and Pelle Stolt and David Cameron Wraith},
  journal={Neurology},
  year={2018},
  volume={90 11},
  pages={e955-e962}
}
OBJECTIVE To assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance. METHODS Two open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX… CONTINUE READING